.After a few years in biotech, Mike Quigley, Ph.D., is going back to the pharma crease, taking up the top science place at Sanofi.Quigley will start Sept. 30 as the French Big Pharma's main medical policeman and also international director of study, Sanofi informed Intense Biotech in an emailed statement.Quigley is actually substituting Frank Nestle, M.D., who left Sanofi this springtime amid a worldwide overhaul of the provider's R&D unit. Nestle, that spent 8 years along with the pharma, dove over to Deerfield Management, where he currently functions as a companion on the therapies staff as well as chief executive officer of the agency's restorative discovery and also growth operations.
Quigley will join Sanofi from a San Francisco-based biotech that resides in stealth, according to his LinkedIn account. He's presently listed as the company's founder, president and CEO.Due to the fact that August 2021, Quigley has actually served as a project partner at SV Health and wellness Investors, a healthcare fund manager with present financial investments in biotechs like BioAge, Cerevance, Dualitas Therapies as well as Nimbus Rehabs, to name a few. Quigley previously held the best area at Dualitas, a biotech that continues to be in stealth, depending on to STAT.The soon-to-be Sanofi leader additionally recently helmed Therini Bio, an immunotherapy biotech working to establish procedures for neurodegenerative health conditions driven by general dysfunction.Just before investing the final few years in biotech, Quigley possesses an also longer performance history in Huge Pharma, very most just recently working as Gilead's senior vice president of research study biology until the summer season of 2021. Before that, he clocked in much more than 4 years throughout numerous management jobs at Bristol Myers Squibb and also acted as a scientific director at Johnson & Johnson's Janssen arm before that.Sanofi claimed Quigley's purpose in his new job will be to "maximize our likelihood of excellence with ideal partnerships all over our institution and also beyond, taking best-in-class innovation in addition to developing and also sourcing new industry-leading talent along with a devotion to diversity," according to an interior memorandum gotten through STAT.